Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

ClinicalTrials.gov ID: NCT01870778

Public ClinicalTrials.gov record NCT01870778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Study identification

NCT ID
NCT01870778
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
6,600 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2, 2013 (Actual)
Primary completion
Jan 23, 2017 (Actual)
Completion
Feb 1, 2017 (Actual)
Last update posted
Mar 30, 2018

2013 – 2017

United States locations

U.S. sites
105
U.S. states
30
U.S. cities
79
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35801 —
Novartis Investigative Site Montgomery Alabama 36106 —
Novartis Investigative Site Tucson Arizona 85723-0001 —
Novartis Investigative Site Anaheim California 92801 —
Novartis Investigative Site Fresno California 93720 —
Novartis Investigative Site Loma Linda California 92354 —
Novartis Investigative Site Los Angeles California 90033 —
Novartis Investigative Site Los Angeles California 90073 —
Novartis Investigative Site Los Angeles California 90095 —
Novartis Investigative Site Northridge California 91325 —
Novartis Investigative Site Palo Alto California 94304-1207 —
Novartis Investigative Site Sacramento California 95817-1460 —
Novartis Investigative Site San Diego California 92103 —
Novartis Investigative Site San Diego California 92123 —
Novartis Investigative Site San Diego California 92161 —
Novartis Investigative Site Sylmar California 91342 —
Novartis Investigative Site Walnut Creek California 94598 —
Novartis Investigative Site Colorado Springs Colorado 80909 —
Novartis Investigative Site Denver Colorado 80204-4507 —
Novartis Investigative Site Hartford Connecticut 06102 —
Novartis Investigative Site Hartford Connecticut 06105 —
Novartis Investigative Site Atlantis Florida 33462 —
Novartis Investigative Site Jacksonville Florida 32207 —
Novartis Investigative Site Jacksonville Florida 32209 —
Novartis Investigative Site Jacksonville Florida 32216 —
Novartis Investigative Site Sanford Florida 32771 —
Novartis Investigative Site Sarasota Florida 34239 —
Novartis Investigative Site Tampa Florida 33606 —
Novartis Investigative Site Tampa Florida 33612 —
Novartis Investigative Site Winter Haven Florida 33881 —
Novartis Investigative Site Atlanta Georgia 30310 —
Novartis Investigative Site Atlanta Georgia 30342 —
Novartis Investigative Site Marietta Georgia 30060 —
Novartis Investigative Site Chicago Illinois 60637 —
Novartis Investigative Site Elk Grove Village Illinois 60007 —
Novartis Investigative Site Oakbrook Terrace Illinois 60181 —
Novartis Investigative Site Peoria Illinois 61602 —
Novartis Investigative Site Indianapolis Indiana 46202-5111 —
Novartis Investigative Site Indianapolis Indiana 46237 —
Novartis Investigative Site Muncie Indiana 47303-3400 —
Novartis Investigative Site Kansas City Kansas 66160 —
Novartis Investigative Site Alexandria Louisiana 71301 —
Novartis Investigative Site Baton Rouge Louisiana 70808 —
Novartis Investigative Site Covington Louisiana 70433 —
Novartis Investigative Site New Orleans Louisiana 70112 —
Novartis Investigative Site Annapolis Maryland 21401 —
Novartis Investigative Site Baltimore Maryland 21201 —
Novartis Investigative Site Baltimore Maryland 21287 —
Novartis Investigative Site Boston Massachusetts 02114 —
Novartis Investigative Site Boston Massachusetts 02115 —
Novartis Investigative Site Boston Massachusetts — —
Novartis Investigative Site Worcester Massachusetts 01655 —
Novartis Investigative Site Detroit Michigan 48201 —
Novartis Investigative Site Detroit Michigan 48202 —
Novartis Investigative Site Detroit Michigan 48235 —
Novartis Investigative Site Minneapolis Minnesota 55417 —
Novartis Investigative Site Jackson Mississippi 39216 —
Novartis Investigative Site Picayune Mississippi 39466 —
Novartis Investigative Site Kansas City Missouri 64108 —
Novartis Investigative Site St Louis Missouri 63110 —
Novartis Investigative Site St Louis Missouri 63128 —
Novartis Investigative Site St Louis Missouri 63136 —
Novartis Investigative Site Omaha Nebraska 68198 —
Novartis Investigative Site Brooklyn New York 11203 —
Novartis Investigative Site Brooklyn New York 11215 —
Novartis Investigative Site Kingston New York 12401 —
Novartis Investigative Site New Hyde Park New York 11040 —
Novartis Investigative Site Rochester New York 14642 —
Novartis Investigative Site Stony Brook New York 11794 —
Novartis Investigative Site The Bronx New York 10461 —
Novartis Investigative Site The Bronx New York 10467-2490 —
Novartis Investigative Site Chapel Hill North Carolina 27599-7075 —
Novartis Investigative Site Durham North Carolina 27710 —
Novartis Investigative Site Raleigh North Carolina 27610 —
Novartis Investigative Site Canton Ohio 44710 —
Novartis Investigative Site Cincinnati Ohio 45220 —
Novartis Investigative Site Cincinnati Ohio 45267-0585 —
Novartis Investigative Site Cleveland Ohio 44195 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Toledo Ohio 43614 —
Novartis Investigative Site Portland Oregon 97219 —
Novartis Investigative Site Abington Pennsylvania 19001 —
Novartis Investigative Site Natrona Heights Pennsylvania 15065 —
Novartis Investigative Site Philadelphia Pennsylvania 19102 2293 —
Novartis Investigative Site Philadelphia Pennsylvania 19107 —
Novartis Investigative Site Wynnewood Pennsylvania 19096 —
Novartis Investigative Site Providence Rhode Island 02903 —
Novartis Investigative Site Warwick Rhode Island 02886 —
Novartis Investigative Site Greenville South Carolina 29607 —
Novartis Investigative Site Greenville South Carolina 29615 —
Novartis Investigative Site Nashville Tennessee 37203 —
Novartis Investigative Site Nashville Tennessee 37212 —
Novartis Investigative Site Dallas Texas 75216 —
Novartis Investigative Site Dallas Texas 75226 —
Novartis Investigative Site Galveston Texas 77555 —
Novartis Investigative Site Houston Texas 77030 —
Novartis Investigative Site San Antonio Texas 78229 —
Novartis Investigative Site San Antonio Texas 78234 —
Novartis Investigative Site Charlottesville Virginia 22908 —
Novartis Investigative Site Falls Church Virginia 22042 —
Novartis Investigative Site Lynchburg Virginia 24501 —
Novartis Investigative Site Roanoke Virginia 24014 —
Novartis Investigative Site Seattle Washington 98101 —
Novartis Investigative Site Seattle Washington 98122 —
Novartis Investigative Site Morgantown West Virginia 26506 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 435 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01870778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2018 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01870778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →